MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 598056 | Name: Sdz 280 446

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Sdz 280 446 is on of the the most active cyclopeptolide of various resistance-modifying agents in restoring rhodamine-123 retention within multidrug resistant P388 cells.

Chemical Structure

Sdz 280 446
Sdz 280 446
CAS#129893-84-1

Theoretical Analysis

MedKoo Cat#: 598056

Name: Sdz 280 446

CAS#: 129893-84-1

Chemical Formula: C61H99N9O14

Exact Mass: 1181.7311

Molecular Weight: 1182.51

Elemental Analysis: C, 61.96; H, 8.44; N, 10.66; O, 18.94

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Sdz 280 446; Sdz 280-446; Sdz 280,446;
IUPAC/Chemical Name
tert-butyl 2-((3S,6R,9S,12S,15S,21S,24S,27S,33aS)-12,15-di((S)-sec-butyl)-3,6,21-triisopropyl-24-(4-methoxybenzyl)-2,8,11,14,20,27-hexamethyl-1,4,7,10,13,16,19,22,25,28-decaoxodotriacontahydropyrido[2,1-a1][1]oxa[4,7,10,13,16,19,22,25,28]nonaazacyclotriacontin-9-yl)acetate
InChi Key
UGWMRFXIOXUDPM-ZBQJDPNTSA-N
InChi Code
InChI=1S/C61H99N9O14/c1-21-37(9)50-52(73)62-33-45(71)66(16)48(35(5)6)53(74)63-42(31-40-26-28-41(82-20)29-27-40)60(81)83-39(11)55(76)70-30-24-23-25-43(70)56(77)67(17)49(36(7)8)54(75)64-47(34(3)4)58(79)65(15)44(32-46(72)84-61(12,13)14)57(78)69(19)51(38(10)22-2)59(80)68(50)18/h26-29,34-39,42-44,47-51H,21-25,30-33H2,1-20H3,(H,62,73)(H,63,74)(H,64,75)/t37-,38-,39-,42-,43-,44-,47+,48-,49-,50-,51-/m0/s1
SMILES Code
CN([C@@H](C(C)C)C(N[C@H](C(C)C)C(N([C@@H](CC(OC(C)(C)C)=O)C(N([C@H](C(N([C@H](C(NCC(N(C)[C@@H](C(C)C)C(N[C@@H](Cc1ccc(OC)cc1)C(O[C@H]2C)=O)=O)=O)=O)[C@@H](C)CC)C)=O)[C@@H](C)CC)C)=O)C)=O)=O)C([C@@H]3CCCCN3C2=O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 1,182.51 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Pourtier-Manzanedo A, Didier AD, Muller CD, Loor F. SDZ PSC 833 and SDZ 280-446 are the most active of various resistance-modifying agents in restoring rhodamine-123 retention within multidrug resistant P388 cells. Anticancer Drugs. 1992 Aug;3(4):419-25. PubMed PMID: 1421439. 2: Jachez B, Nordmann R, Loor F. Restoration of taxol sensitivity of multidrug-resistant cells by the cyclosporine SDZ PSC 833 and the cyclopeptolide SDZ 280-446. J Natl Cancer Inst. 1993 Mar 17;85(6):478-83. PubMed PMID: 8095304. 3: Didier AD, Loor F. Decreased biotolerability for ivermectin and cyclosporin A in mice exposed to potent P-glycoprotein inhibitors. Int J Cancer. 1995 Oct 9;63(2):263-7. PubMed PMID: 7591215. 4: Tiberghien F, Loor F. Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay. Anticancer Drugs. 1996 Jul;7(5):568-78. PubMed PMID: 8862725. 5: Pourtier-Manzanedo A, Didier A, Loor F. Expression of P-glycoprotein on normal lymphocytes: enhancement of the doxorubicin-sensitivity of concanavalin A-responding mouse spleen cells by P-glycoprotein blockers. Oncol Res. 1992;4(11-12):473-80. PubMed PMID: 1363723. 6: Jachez B, Loor F. Atypical multi-drug resistance (MDR): low sensitivity of a P-glycoprotein-expressing human T lymphoblastoid MDR cell line to classical P-glycoprotein-directed resistance-modulating agents. Anticancer Drugs. 1993 Dec;4(6):605-15. PubMed PMID: 7905300. 7: Boesch D, Loor F. Extent and persistence of P-glycoprotein inhibition in multidrug-resistant P388 cells after exposure to resistance-modifying agents. Anticancer Drugs. 1994 Apr;5(2):229-38. PubMed PMID: 7914109. 8: Lehne G, Mørkrid L, den Boer M, Rugstad HE. Diverse effects of P-glycoprotein inhibitory agents on human leukemia cells expressing the multidrug resistance protein (MRP). Int J Clin Pharmacol Ther. 2000 Apr;38(4):187-95. PubMed PMID: 10783828. 9: Emmer G, Grassberger MA, Schulz G, Boesch D, Gavériaux C, Loor F. Derivatives of a novel cyclopeptolide. 2. Synthesis, activity against multidrug resistance in CHO and KB cells in vitro, and structure-activity relationships. J Med Chem. 1994 Jun 24;37(13):1918-28. PubMed PMID: 8027973. 10: Lehne G, De Angelis P, den Boer M, Rugstad HE. Growth inhibition, cytokinesis failure and apoptosis of multidrug-resistant leukemia cells after treatment with P-glycoprotein inhibitory agents. Leukemia. 1999 May;13(5):768-78. PubMed PMID: 10374882. 11: Jachez B, Cianfriglia M, Loor F. Modulation of human P-glycoprotein epitope expression by temperature and/or resistance-modulating agents. Anticancer Drugs. 1994 Dec;5(6):655-65. PubMed PMID: 7534147. 12: Adams SM, Sharp MG, Walker RA, Brammar WJ, Varley JM. Differential expression of translation-associated genes in benign and malignant human breast tumours. Br J Cancer. 1992 Jan;65(1):65-71. PubMed PMID: 1370760; PubMed Central PMCID: PMC1977345. 13: Didier A, Wenger J, Loor F. Decreased uptake of cyclosporin A by P-glycoprotein (Pgp) expressing CEM leukemic cells and restoration of normal retention by Pgp blockers. Anticancer Drugs. 1995 Oct;6(5):669-80. PubMed PMID: 8845477.

View History

Sdk 12B-5

Sdk 12B-5